OYST - Oyster Point's nasal spray to be covered by largest Medicare pharmacy benefit manager
- Oyster Point Pharma ( NASDAQ: OYST ) on Wednesday said its nasal spray Tyrvaya for the treatment of dry eye disease would now be covered by the largest Medicare pharmacy benefit manager (PBM) in the U.S.
- OYST did not name the PBM in its statement .
- Tyrvaya would be added by the PBM on its Medicare part D formularies, effective Sept. 1, OYST said.
- "In the United States, almost half of the total dry eye disease prescriptions are covered by Medicare...," OYST CEO Jeffrey Nau said.
- OYST in its Q2 earning report last week said Tyrvaya brought in net product revenue of $4.7M, and that there were about 30K Tyrvaya prescriptions filled during the quarter.
For further details see:
Oyster Point's nasal spray to be covered by largest Medicare pharmacy benefit manager